Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron Ltd to develop vaccine for deadly bacillary dysentery with U.S. Army research unit

Immuron Ltd to develop vaccine for deadly bacillary dysentery with U.S. Army research unit

Immuron Ltd (ASX:IMC) will collaborate with the Walter Reed Army Institute of Research (WRAIR) in the U.S to develop a vaccine to fight the often deadly Shigellosis, also known as bacillary dysentery.

There is currently no approved vaccine for bacillary dysentery, which is ranked number two in the 2015 Global Rank List of Infectious Disease Threats for the U.S. military.

It also results in one million deaths annually - according to a World Health Organisation report.

The symptoms include diarrhea (often bloody), fever and stomach cramps starting a day or two after exposure.

Based in Silver Spring, Maryland, and established in 1893, the Walter Reed Army Institute of Research (WRAIR)
is the oldest, largest, and most diverse military biomedical research institute within the U.S. Department of Defense.

The research and development collaboration agreement with the largest military biomedical research facility in the U.S. highlights the promise of Immuron’s oral immunotherapy platform.

One of WRAIR’s missions is to develop therapeutics for the prevention and the treatment of infectious diseases.

The long term goal of this collaboration is to develop therapeutics that can be utilized for both commercial and government use.

Immuron generated growing revenues from OTC products of $1.1 million in FY2015 and the company has forecast that its Travelan product will generate revenues of $4.6 million in FY 2017.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full IMC profile View Profile

Immuron Ltd Timeline

June 08 2017
May 30 2017
May 27 2016

Related Articles

couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects
nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
pipette and petri dish
June 20 2018
As well as developing its lead compound, Silence has also been busy taking its larger rivals to court over alleged patent infringements

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use